Overview

Bioavailability of Apixaban Sprinkle Compared to Apixaban Capsules

Status:
Completed
Trial end date:
2018-06-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the absorption of apixaban (BMS-562247) into the bloodstream of healthy volunteers, when administered as sprinkle capsules compared to tablets. Eligible participants will be randomly assigned to 1 of 2 treatment sequences and will receive a single oral dose of apixaban twice during the course of the study.
Phase:
Phase 1
Details
Lead Sponsor:
Bristol-Myers Squibb
Treatments:
Apixaban